Phase 2 Lymphoma Trial, Recruiting NCT00501826 Sponsor: M.D. Anderson Cancer Center Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT00501826
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have T cell acute lymphoblastic leukaemia (ALL) or T cell lymphoblastic lymphoma that has not previously been treated, including those whose cancer did not respond to one initial round of chemotherapy, or those whose cancer is in remission after no more than two rounds of chemotherapy.
  • People whose overall health and ability to carry out daily activities meets a certain minimum level, as measured by a standard medical scoring system (confirm with trial site).
  • People whose liver function blood test results are within acceptable ranges, as determined by the trial team.
  • People whose kidney function blood test results are within acceptable ranges, as determined by the trial team.

Who may not be able to join:

  • Women who are pregnant or currently breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Farhad Ravandi-Kashani, M.D. Anderson Cancer Center

Phone: 713-745-0394

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
11 July 2007
Est. completion
31 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Complete remission rate; Duration of remission; Progression-free survival; Overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov